Adding to this complexity, BET inhibitors and PROTACs have been shown to suppress IFN-γ production in NK and dendritic cells, alter T cell cytokine profiles, and expand regulatory T cell activity that may compromise anti-tumor immunity. The gene discussed is IFNG; the disease is neoplasm.